Stockscreener 앱 받기
119.35
0.29%
0.35
전일 마감가:
$119.00
열려 있는:
$119.52
하루 거래량:
665.43K
Relative Volume:
0.87
시가총액:
$9.82B
수익:
$51.48M
순이익/손실:
$-315.00M
주가수익비율:
-33.42
EPS:
-3.5708
순현금흐름:
$-244.00M
1주 성능:
+5.14%
1개월 성능:
+52.56%
6개월 성능:
+59.62%
1년 성능:
+163.99%
1일 변동 폭
$114.00
$120.60
1주일 범위
$111.21
$120.90
52주 변동 폭
$36.65
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
119.35 | 9.82B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 재개 | Guggenheim | Buy |
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Insider Monkey
Kymera jumps 17% on early enrollment completion in skin disease study - MSN
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Warren Buffett, Ray Dalio, Scion Asset Management, Brevan Howard, Kymera Therapeutics Inc (KYMR), Sony Group Corp (SONY), and More - Insider Monkey
(KYMR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock - Moomoo
Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com - Investing.com India
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock - Investing.com
Form 144 Kymera Therapeutics For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics, Inc. Announces Appointment of Elizabeth Laws as Senior Vice President - marketscreener.com
Kymera hires ex-Sanofi executive to lead KT-621 development - Investing.com
Kymera hires ex-Sanofi executive to lead KT-621 development By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader - The Manila Times
Kymera Therapeutics Insider Sold Shares Worth $8,864,829, According to a Recent SEC Filing - Moomoo
KYMRKymera Therapeutics Inc Options - Finviz
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade) (NASDAQ:KYMR) - Seeking Alpha
Kymera: Building Toward A Defining 2H26 Moment (NASDAQ:KYMR) - Seeking Alpha
Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift - Yahoo Finance
Kymera Therapeutics(KYMR.US) Officer Sells US$9.22 Million in Common Stock - Moomoo
How Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investors - Yahoo Finance
Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics I - GuruFocus
Kymera Therapeutics director Bruce Booth sells $8.28m in shares By Investing.com - Investing.com Australia
Kymera Therapeutics director Bruce Booth sells $8.28m in shares - Investing.com
Form 4 Kymera Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 144 Kymera Therapeutics For: 2 July By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed? - Sahm
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug - Yahoo Finance
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
Kymera Therapeutics director sells $56.5m in shares - Investing.com UK
Form 4 Kymera Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
Kymera Therapeutics director sells $56.5m in shares By Investing.com - Investing.com South Africa
Kymera Therapeutics director Booth sells $3.42 million in KYMR shares - Investing.com
Kymera Therapeutics director Booth sells $3.42 million in KYMR shares By Investing.com - Investing.com India
Kymera Therapeutics(KYMR.US) Director Sells US$59.88 Million in Common Stock - Moomoo
BofA Securities Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $125 - Moomoo
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $125 - Moomoo
KYMR Maintained by B of A Securities -- Price Target Raised to $125 - GuruFocus
KYMR Maintained by B. Riley Securities -- Price Target Raised to $155 - GuruFocus
Form 144 KYMERA THERAPEUTICS For: 29 June By Investing.com - Investing.com Nigeria
KYMR Maintained by Truist Securities -- Price Target Raised to $136 - GuruFocus
B. Riley Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $155 - Moomoo
Kymera Therapeutics, Inc.(NasdaqGM: KYMR) added to Russell 2000 Value Benchmark - marketscreener.com
Truist raises Kymera Therapeutics price target on AD timeline By Investing.com - Investing.com Canada
B. Riley Adjusts Kymera Therapeutics Price Target to $155 From $117, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):